CRO Platform Trial.Link Receives CNY 600 Mn in Series C+ and D
Trail.Link, as the pilot contract research organizer (CRO) platform in China, announced to receive bankrolls of over CNY 600 million during the last two fundraisings within only eight months.
In the most recent Series D, GGV and Vplus Capital co-led the deal, participated by the current equity holder Matrix Partners China and Eastern Bell Capital. The bankroll will assist the CRO tech platform in standardizing drug development and promoting facility construction.
The first Chinese CRO platform focuses on shortening the R&D cycle and lowering the research cost for innovative drug developers.